| 2016-11-21 07:13:07|
CEMP 07:13 11/21 11/21/16
Cempra downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Ritu Baral downgraded Cempra to Market Perform from Outperform. The analyst believes its solithromycin approval will come with safety warnings and possibly REMS, limiting commercial adoption to $539M in peak U.S. sales. The downgrade is based on the lack of clarity on the company's path forward. Baral removed her price target on Cempra, which was previously $13.